Vanguard L

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Aktiivinen ainesosa:

Leptospira canicola, Leptospira icterohaemorrhagiae

Saatavilla:

Pfizer Ltd

ATC-koodi:

QI07AB01

INN (Kansainvälinen yleisnimi):

Leptospira canicola, Leptospira icterohaemorrhagiae

Valtuutuksen tilan:

Expired

Valmisteyhteenveto

Issued 03/12/2009 – AN 00585/2009
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vanguard

L
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Quantity per 1 ml dose
ACTIVE SUBSTANCES:
Inactivated _Leptospira canicola_, at least 40 hamster protective
doses.
Inactivated _Leptospira icterohaemorrhagiae_, at least 40 hamster
protective doses.
See Section 6.1 for full list of excipients.
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Canine from 7 weeks of age.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to reduce clinical signs and infection due
to _Leptospira canicola_
and _Leptospira icterohaemorrhagiae_.
Onset of immunity occurs by approximately two weeks after the last
dose of the Basic
Vaccination Scheme.
The duration of immunity is at least 12 months.
4.3
CONTRAINDICATIONS
Do not use in unhealthy animals.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
1/4
Issued 03/12/2009 – AN 00585/2009
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL
PRODUCT TO ANIMALS
In case of accidental self-injection, wash the area immediately with
water. If symptoms
develop, seek medical attention showing a copy of the product
literature.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Vaccinated dogs may have a transient swelling 4-6 hours after
vaccination which resolves
after approximately 7 days.
If a systemic anaphylactic reaction occurs (eg vomiting), administer
adrenaline or an
equivalent.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Do not use during pregnancy.
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
No information is available on the safety and efficacy of this vaccine
when used with any
other veterinary medicinal product except vaccines from the Vanguard
range containing
canine distemper virus, canine parvovirus, canine adenovirus or canine
parainfluenza virus.